根据法国研究者的结果，某些多灶性运动神经病患者，无论有无外在传导阻滞症状，都可以对免疫球蛋白IV作出反应。
该研究的首席科学家Emilien Delmont博士说：“这表明临床判断仍然是诊断多灶性运动神经病的金标准。
因此，IVIg或许可以作为处方药供慢性非对称运动肌无力的备选病人使用。即使这些病人经神经传导测试检测其外周神经分布并无传导阻滞症状。
在今年8月的《Neurology,》杂志上，法国尼斯市巴斯德医院的Delmont博士和他的同事们提到，他们研究了20名存在传导阻滞症状和13名不存在这种症状的病人，根据研究数据得出的这个结论。随访这些病人已经超过4年时间。所有病人均患有非对称的运动肌无力但并没有感觉、球麻痹和呼吸方面的症状，且不牵涉上位神经元。
组间并没有观察到显著区别，但在无传导阻滞症状的病人中，牵涉中位神经元的情况显著较少。近端肌无力也存在这种情况。
的治疗效果两组很相近不存在传导阻滞症状的病人中有8（61%）人对这种治疗有反应，而存在这种症状的病人中有14（70%）人有反应。
马里兰州巴尔地摩市约翰霍普金斯大学医学院的Vinay Chaudhry博士，也是这篇文章的共同通讯作者，他说他认同这种方法。
他说：“[glow=255,red,2][glow=255,red,2]关于IVIg的实验证实它可以用于在多灶性外周神经分布处患有进展性非对称末端肌无力的病人即使这些病人在神经传导测试中发现并无神经阻滞症状。”
备注：
多灶性运动神经病是近年来才被认识的少见的获得性免疫介导的神经病，多为缓慢隐匿性起病，以非对称性肌无力、肌萎缩、肌束颤动、腱反射降低为特征，无呼吸肌麻痹、无脑神经受累、无感觉障碍、无锥体束征。有文献报道多灶性运动神经病可以用大量免疫球蛋白注射治疗，约80%～90%患者症状可缓解。
英文原文：
Immunoglobulin May Be Useful in Multifocal Motor Neuropath
Certain patients with multifocal motor neuropathy with or without apparent conduction block respond to IV immunoglobulin (IVIg) therapy, according to French researchers.
"This study shows that clinical judgment remains the gold standard in diagnosis of multifocal motor neuropathies," lead investigator Dr. Emilien Delmont told Reuters Health.
"Hence, a trial of IVIg may be prescribed for selected patients presenting with chronic asymmetric motor weakness with a peripheral nerve distribution without any conduction block being detected in the nerve conduction study," he added.
In the August issue of Neurology, Dr. Delmont of Hopital Pasteur, Nice and colleagues note that they came to this conclusion after studying data on 20 such patients with conduction block and 13 without. They had been followed for more than 4 years. All had asymmetric motor weakness without sensory, bulbar or respiratory signs, and no upper motor neuron involvement.
Few significant differences were seen between groups, but involvement of the median nerve was significantly less frequent in patients without conduction block. This was also true of proximal weakness.
The efficacy of IVIG was similar in both groups, with responses in 8 (61%) of patients without conduction block and 14 (70%) with conduction block.
Dr. Vinay Chaudhry of Johns Hopkins University School of Medicine, Baltimore, Maryland, author of an accompanying editorial, told Reuters Health that he agreed with the approach.
"A trial of IVIg may be justified in patients with progressive distal asymmetric weakness in a multifocal peripheral nerve distribution even if they don't have conduction block on nerve conduction studies," he said.
